Loading
Tumours fill with immune cells that protect them. Earlier drugs tried to remove those cells and failed. Newer ones aim to switch them to the attacking side.
CSF1R inhibitors depleted macrophages broadly and produced little benefit outside tenosynovial giant cell tumour, plausibly because depletion removes useful cells alongside harmful ones. TREM2, MARCO and LILRB2 mark specific suppressive macrophage states in human tumour single-cell atlases, and antibodies against them are in early trials. The proposition is state-switching, verified by on-treatment biopsies, rather than depletion.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, Monoclonal antibodies.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, Colorectal cancer.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment, Glioma & glioblastoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.